secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0000950170-24-096177
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q2 2024: Cash $352M; FT819 SLE study adds Cy; FT522 first patient without conditioning
--------------------------------------------------------------------------------

- Cash, equivalents & investments $352.0M; projected operating runway through YE26.
- Revenue $6.8M (incl. $5M milestone from Ono); GAAP operating expenses $51.9M (R&D $34.6M, G&A $17.3M).
- FT819 Phase 1 SLE study: first patient (lupus nephritis) dosed; protocol amended to include single-agent cyclophosphamide; no Grade≥3 AEs, no CRS/ICANS/GvHD.
- FT825/ONO-8250 Phase 1 solid tumor study: three patients treated as monotherapy; combo dosing with mAb expected 3Q24.
- FT522 Phase 1 BCL study: first patient treated without conditioning chemotherapy at 300M cells/dose; IND for autoimmune basket study planned 3Q24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024096177/0000950170-24-096177-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017024096177/fate-20240813.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096177

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer